Masimo Corp (MASI) Stock Analysis and Metrics

Masimo

NASDAQ: MASI

$179.95 ▲ +0.00 (+0.00%)

At close: Jun 12, 2026 · 4:00 PM UTC

Financial Ratios

Market Cap9.39 Bn

P/E-66.86

P/S6.03

Div. Yield0.00

Total Debt (Qtr)452.00 Mn

Revenue Growth (1y) (Qtr)8.49

Add ratio to table…

About

Masimo Corp develops and produces industry-leading monitoring technologies for healthcare settings, including innovative measurements, sensors, and patient monitors. The company leverages the Masimo Hospital Automation™ and Masimo SafetyNet® platforms to improve and automate care delivery through connectivity, automation, and telehealth solutions. Its core activities focus on noninvasive patient monitoring technologies, hospital automation, and remote monitoring devices for use in hospitals and other care environments.

Masimo generates revenue by selling its products to hospitals, emergency medical service providers, home care providers, physician offices, veterinarians, and long-term care facilities through its direct sales force, distributors, and original equipment manufacturer (OEM) partners such as GE Healthcare, Hillrom, Mindray, Philips, Physio-Control, and Zoll. Revenue is derived from monitors or circuit boards, proprietary single-patient use or reusable sensors, software, and cables. The company's core measurement technologies include Masimo Signal Extraction Technology® (SET®) pulse oximetry and advanced rainbow® Pulse CO-Oximetry parameters like noninvasive hemoglobin (SpHb®).

Masimo Corp operates through the following segments:

• Healthcare: This segment develops, manufactures, and markets noninvasive patient monitoring technologies, hospital automation® and connectivity solutions, and remote monitoring devices. The segment's products include monitors or circuit boards, proprietary single-patient use or reusable sensors, software, and cables. Key technologies include Masimo Signal Extraction Technology® (SET®) pulse oximetry and Masimo rainbow® Pulse CO-Oximetry, with specific products such as the Root® Patient Monitoring and Connectivity Hub, Radius PPG®, Radius VSM®, and Masimo SafetyNet® remote patient surveillance solution.

• Non-healthcare: As of December 28, 2024, the non-healthcare consumer business remained part of the Company’s continuing operations, but was being evaluated for divestiture. Subsequent to year end, the sales evaluation process continued to progress in early 2025, and as of March 29, 2025, the non-healthcare consumer business was classified as held-for-sale and reported as discontinued operations. The non-healthcare consumer business was previously operated under Sound United, which included the Viper Holdings Corporation and its subsidiaries.

Masimo holds a leading position in the patient monitoring industry, particularly in pulse oximetry, where its Masimo SET® technology is trusted by clinicians to monitor over 200 million patients annually and is the primary technology used by all top ten hospitals in the 2024-2025 U. S. News & World Report Best Hospitals Honor Roll. The company competes with major players such as Medtronic plc, GE Healthcare, Philips, and large technology firms like Apple, Samsung, and Amazon that are expanding into healthcare. Its competitive advantages stem from proprietary signal processing algorithms, strong intellectual property protection, and widespread clinical validation of its technologies.

Masimo serves hospitals, emergency medical service providers, home care providers, physician offices, veterinarians, and long-term care facilities. Specific customer names mentioned include GE Healthcare, Hillrom, Mindray, Philips, Physio-Control, and Zoll as OEM partners. The company also works with group purchasing organizations (GPOs), having contracts with the five largest national GPOs in the U. S. based on negotiated purchase volume.

Investment Thesis

▲ Bull case

Masimo's merger with Danaher presents a compelling value proposition for shareholders due to the $180 per share cash offer, which represents a significant premium over recent trading levels and reflects Danaher's confidence in Masimo's standalone growth trajectory within its Diagnostics segment. This valuation implies that Danaher is willing to pay for Masimo's established market leadership in non-invasive monitoring, particularly its SET® pulse oximetry technology used on over 200 million patients annually and its status as the primary oximeter in all top 10 U.S. hospitals per Newsweek rankings, suggesting strong recurring revenue potential from installed base and consumables. The transaction structure preserves Masimo as an independent operating company, allowing it to retain operational focus while gaining access to Danaher's global commercial infrastructure, capital resources, and best-in-class operational discipline, which could accelerate international expansion and R&D investment without diluting Masimo's innovative culture or brand equity. The market may be underestimating how Danaher's scale and expertise in diagnostics and life sciences could unlock new growth avenues for Masimo's Hospital Automation™ and SafetyNet® platforms, particularly in integrating patient monitoring data with broader clinical workflows and electronic health records, creating stickier solutions that drive higher utilization and pricing power. Furthermore, the preliminary Q4 and full-year 2025 results showing 12% reported revenue growth and non-GAAP EPS exceeding $1.54 and $5.55 respectively—despite tariff headwinds—demonstrate underlying business resilience, with constant currency growth confirming organic strength, suggesting the core franchise remains vibrant and capable of sustaining mid-single-digit growth post-merger, which Danaher can leverage to exceed standalone projections.
The ongoing legal vindication in Masimo's favor against Apple, highlighted by the federal jury award of $634 million in November 2025 for patent infringement related to blood-oxygen technology, represents an underappreciated catalyst that could significantly enhance Masimo's long-term competitive position and financial flexibility, even as the merger proceeds. This judgment not only validates the strength of Masimo's intellectual property portfolio—particularly around foundational SET® and rainbow SET™ technologies—but also establishes a legal precedent that may deter future infringement attempts by major tech players seeking to enter the medical monitoring space, thereby protecting Masimo's core franchise value. While the merger with Danaher will ultimately determine Masimo's ownership structure, the accrual of this judgment (or potential settlement proceeds) could strengthen Masimo's balance sheet pre-close or contribute to Danaher's post-acquisition integration value, offsetting concerns about litigation costs that have historically weighed on sentiment. The market appears to be overlooking how this legal win reinforces Masimo's technological moat in non-invasive sensing, especially as wearable health monitoring expands, and could deter regulatory or competitive challenges to Masimo's dominance in clinical pulse oximetry, where it already holds near-universal adoption in top-tier U.S. hospitals. This intellectual property advantage, combined with Masimo's shift to a pure-play medtech firm after divesting Sound United, positions the combined entity to capitalize on growing demand for reliable, hospital-grade monitoring in home and ambulatory settings—a trend Danaher is well-equipped to scale globally through its diagnostics and life sciences channels.
Masimo's strategic pivot toward recurring revenue models through its Hospital Automation™ and SafetyNet® platforms, evidenced by record incremental contract value from new customers and expanded hospital agreements in 2025, is creating a more predictable and resilient earnings base that the market is not fully pricing into the merger consideration. These platforms enable Masimo to move beyond one-time device sales toward subscription-based data analytics, remote patient monitoring, and care coordination services, which typically carry higher gross margins and lower revenue volatility—characteristics highly prized by Danaher in its acquisition strategy. The preliminary 2025 results showing 9% full-year revenue growth on both reported and constant currency bases, coupled with 11% constant currency Q4 growth, indicate that this transition is gaining traction despite macroeconomic headwinds, with international markets benefiting from the shift to a distributor model that reduces working capital strain while expanding reach. Danaher's expertise in scaling SaaS and technology-enabled services across its diagnostics portfolio could accelerate the adoption of Masimo's connectivity solutions, particularly in value-based care environments where continuous monitoring reduces complications and readmissions, directly aligning with Masimo's mission to improve outcomes and lower costs. The market may be failing to recognize that this recurring revenue shift could expand Masimo's addressable market beyond traditional hardware into clinical decision support and telehealth, where Danaher's existing relationships with pharmaceutical companies and health systems offer immediate cross-selling opportunities.

Masimo's merger with Danaher presents a compelling value proposition for shareholders due to the $180 per share cash offer, which represents a significant premium over recent trading levels and reflects Danaher's confidence in Masimo's standalone growth trajectory within its Diagnostics segment. This valuation implies that Danaher is willing to pay for Masimo's established market leadership in non-invasive monitoring, particularly its SET® pulse oximetry technology used on over 200 million patients annually and its status as the primary oximeter in all top 10 U.S. hospitals per Newsweek rankings, suggesting strong recurring revenue potential from installed base and consumables. The transaction structure preserves Masimo as an independent operating company, allowing it to retain operational focus while gaining access to Danaher's global commercial infrastructure, capital resources, and best-in-class operational discipline, which could accelerate international expansion and R&D investment without diluting Masimo's innovative culture or brand equity. The market may be underestimating how Danaher's scale and expertise in diagnostics and life sciences could unlock new growth avenues for Masimo's Hospital Automation™ and SafetyNet® platforms, particularly in integrating patient monitoring data with broader clinical workflows and electronic health records, creating stickier solutions that drive higher utilization and pricing power. Furthermore, the preliminary Q4 and full-year 2025 results showing 12% reported revenue growth and non-GAAP EPS exceeding $1.54 and $5.55 respectively—despite tariff headwinds—demonstrate underlying business resilience, with constant currency growth confirming organic strength, suggesting the core franchise remains vibrant and capable of sustaining mid-single-digit growth post-merger, which Danaher can leverage to exceed standalone projections.
The ongoing legal vindication in Masimo's favor against Apple, highlighted by the federal jury award of $634 million in November 2025 for patent infringement related to blood-oxygen technology, represents an underappreciated catalyst that could significantly enhance Masimo's long-term competitive position and financial flexibility, even as the merger proceeds. This judgment not only validates the strength of Masimo's intellectual property portfolio—particularly around foundational SET® and rainbow SET™ technologies—but also establishes a legal precedent that may deter future infringement attempts by major tech players seeking to enter the medical monitoring space, thereby protecting Masimo's core franchise value. While the merger with Danaher will ultimately determine Masimo's ownership structure, the accrual of this judgment (or potential settlement proceeds) could strengthen Masimo's balance sheet pre-close or contribute to Danaher's post-acquisition integration value, offsetting concerns about litigation costs that have historically weighed on sentiment. The market appears to be overlooking how this legal win reinforces Masimo's technological moat in non-invasive sensing, especially as wearable health monitoring expands, and could deter regulatory or competitive challenges to Masimo's dominance in clinical pulse oximetry, where it already holds near-universal adoption in top-tier U.S. hospitals. This intellectual property advantage, combined with Masimo's shift to a pure-play medtech firm after divesting Sound United, positions the combined entity to capitalize on growing demand for reliable, hospital-grade monitoring in home and ambulatory settings—a trend Danaher is well-equipped to scale globally through its diagnostics and life sciences channels.
Masimo's strategic pivot toward recurring revenue models through its Hospital Automation™ and SafetyNet® platforms, evidenced by record incremental contract value from new customers and expanded hospital agreements in 2025, is creating a more predictable and resilient earnings base that the market is not fully pricing into the merger consideration. These platforms enable Masimo to move beyond one-time device sales toward subscription-based data analytics, remote patient monitoring, and care coordination services, which typically carry higher gross margins and lower revenue volatility—characteristics highly prized by Danaher in its acquisition strategy. The preliminary 2025 results showing 9% full-year revenue growth on both reported and constant currency bases, coupled with 11% constant currency Q4 growth, indicate that this transition is gaining traction despite macroeconomic headwinds, with international markets benefiting from the shift to a distributor model that reduces working capital strain while expanding reach. Danaher's expertise in scaling SaaS and technology-enabled services across its diagnostics portfolio could accelerate the adoption of Masimo's connectivity solutions, particularly in value-based care environments where continuous monitoring reduces complications and readmissions, directly aligning with Masimo's mission to improve outcomes and lower costs. The market may be failing to recognize that this recurring revenue shift could expand Masimo's addressable market beyond traditional hardware into clinical decision support and telehealth, where Danaher's existing relationships with pharmaceutical companies and health systems offer immediate cross-selling opportunities.

▼ Bear case

Masimo's merger with Danaher carries significant execution risk that the market may be underestimating, particularly regarding regulatory approval timelines and the potential for remedies that could diminish the transaction's value, despite Danaher's $180 per share offer appearing attractive on the surface. The Hart-Scott-Rodino antitrust review process, while routine, could uncover concerns about reduced competition in the patient monitoring space—especially given Masimo's dominant share in clinical pulse oximetry and Danaher's existing presence through its Radiometer blood analyzer line—potentially leading to divestiture requirements or behavioral constraints that limit Masimo's ability to innovate or integrate with Danaher's broader diagnostics offerings. Furthermore, the announcement explicitly notes risks related to Masimo's ability to retain key personnel during the pendency of the merger, which is critical given the company's history of leadership turnover following the Sound United divestiture and activist pressure; losing senior R&D or commercial talent could erode the very innovation engine that Danaher is paying a premium to acquire. The cautionary statement also highlights that the benefits of the merger may not be realized as expected, and with Danaher projecting only a modest 15-20 cent EPS boost in the first full year post-close, the market might be overlooking how integration costs, cultural clashes, or diversion of management focus could delay or dilute synergies, leaving shareholders with cash proceeds but losing exposure to Masimo's standalone upside potential if the deal faces delays or breaks.
Masimo's ongoing vulnerability to tariff impacts and geopolitical supply chain disruptions presents a material risk that is not being sufficiently weighed against the merger's perceived certainty, especially as the company explicitly states that tariff implementation remains a dynamic and uncertain situation that could cause actual results to differ materially from projections. The preliminary 2025 guidance already incorporates the estimated financial impact of new tariffs, net of mitigation efforts, yet acknowledges that these assumptions are subject to change, and with Masimo's global manufacturing footprint and reliance on international component sourcing, any escalation in trade restrictions—particularly those affecting electronics or medical device inputs—could compress margins more severely than anticipated, undermining the non-GAAP EPS strength highlighted in the preliminary results. This risk is compounded by Masimo's shift to a distributor model in some international markets, which, while reducing working capital burden, may also diminish direct control over pricing, service quality, and customer relationships in key overseas regions, making it harder to offset tariff pressures through operational leverage. The market appears to be treating the $180 per share offer as a guaranteed floor, but if regulatory delays or tariff-induced performance shortfalls lead to a renegotiation or termination of the merger agreement, Masimo's standalone stock could revert to pre-announcement levels, especially given its history of volatility tied to Apple litigation outcomes and quarterly execution missteps.
Despite Masimo's strong performance in clinical settings validated by the NeoPODS and INSPIRE studies, the company remains exposed to competitive and technological disruption from large tech firms expanding into health monitoring—a threat that the merger with Danaher may not fully mitigate and that the market is underestimating in the context of Masimo's long-term standalone value. While the Apple lawsuit outcome validates Masimo's patent strength in specific domains, competitors like Medtronic, Philips, and even emerging players from the consumer tech sector (e.g., Google, Samsung) are investing heavily in next-generation sensing technologies, AI-driven analytics, and wearable form factors that could challenge Masimo's dominance in both clinical and emerging home health markets. Danaher's primary expertise lies in diagnostics and life sciences tools, not consumer-facing health wearables or mass-market patient engagement platforms, meaning the merged entity may lack the agility or consumer brand insight needed to counter disruptive innovations that prioritize user experience, continuous data streams, and integration with popular health ecosystems. The market may be overestimating how Danaher's scale can protect Masimo from these threats, when in reality, the company's historical success has been rooted in clinical-grade accuracy and hospital-centric solutions—strengths that may not translate well to decentralized care models where convenience, battery life, and app integration often outweigh marginal gains in measurement precision, leaving Masimo vulnerable to substitution even as it benefits from Danaher's balance sheet support.

Masimo's merger with Danaher carries significant execution risk that the market may be underestimating, particularly regarding regulatory approval timelines and the potential for remedies that could diminish the transaction's value, despite Danaher's $180 per share offer appearing attractive on the surface. The Hart-Scott-Rodino antitrust review process, while routine, could uncover concerns about reduced competition in the patient monitoring space—especially given Masimo's dominant share in clinical pulse oximetry and Danaher's existing presence through its Radiometer blood analyzer line—potentially leading to divestiture requirements or behavioral constraints that limit Masimo's ability to innovate or integrate with Danaher's broader diagnostics offerings. Furthermore, the announcement explicitly notes risks related to Masimo's ability to retain key personnel during the pendency of the merger, which is critical given the company's history of leadership turnover following the Sound United divestiture and activist pressure; losing senior R&D or commercial talent could erode the very innovation engine that Danaher is paying a premium to acquire. The cautionary statement also highlights that the benefits of the merger may not be realized as expected, and with Danaher projecting only a modest 15-20 cent EPS boost in the first full year post-close, the market might be overlooking how integration costs, cultural clashes, or diversion of management focus could delay or dilute synergies, leaving shareholders with cash proceeds but losing exposure to Masimo's standalone upside potential if the deal faces delays or breaks.
Masimo's ongoing vulnerability to tariff impacts and geopolitical supply chain disruptions presents a material risk that is not being sufficiently weighed against the merger's perceived certainty, especially as the company explicitly states that tariff implementation remains a dynamic and uncertain situation that could cause actual results to differ materially from projections. The preliminary 2025 guidance already incorporates the estimated financial impact of new tariffs, net of mitigation efforts, yet acknowledges that these assumptions are subject to change, and with Masimo's global manufacturing footprint and reliance on international component sourcing, any escalation in trade restrictions—particularly those affecting electronics or medical device inputs—could compress margins more severely than anticipated, undermining the non-GAAP EPS strength highlighted in the preliminary results. This risk is compounded by Masimo's shift to a distributor model in some international markets, which, while reducing working capital burden, may also diminish direct control over pricing, service quality, and customer relationships in key overseas regions, making it harder to offset tariff pressures through operational leverage. The market appears to be treating the $180 per share offer as a guaranteed floor, but if regulatory delays or tariff-induced performance shortfalls lead to a renegotiation or termination of the merger agreement, Masimo's standalone stock could revert to pre-announcement levels, especially given its history of volatility tied to Apple litigation outcomes and quarterly execution missteps.
Despite Masimo's strong performance in clinical settings validated by the NeoPODS and INSPIRE studies, the company remains exposed to competitive and technological disruption from large tech firms expanding into health monitoring—a threat that the merger with Danaher may not fully mitigate and that the market is underestimating in the context of Masimo's long-term standalone value. While the Apple lawsuit outcome validates Masimo's patent strength in specific domains, competitors like Medtronic, Philips, and even emerging players from the consumer tech sector (e.g., Google, Samsung) are investing heavily in next-generation sensing technologies, AI-driven analytics, and wearable form factors that could challenge Masimo's dominance in both clinical and emerging home health markets. Danaher's primary expertise lies in diagnostics and life sciences tools, not consumer-facing health wearables or mass-market patient engagement platforms, meaning the merged entity may lack the agility or consumer brand insight needed to counter disruptive innovations that prioritize user experience, continuous data streams, and integration with popular health ecosystems. The market may be overestimating how Danaher's scale can protect Masimo from these threats, when in reality, the company's historical success has been rooted in clinical-grade accuracy and hospital-centric solutions—strengths that may not translate well to decentralized care models where convenience, battery life, and app integration often outweigh marginal gains in measurement precision, leaving Masimo vulnerable to substitution even as it benefits from Danaher's balance sheet support.

Peer Comparison

Companies in the Medical Devices

S.No.	Ticker	Company	Market Cap	P/E	P/S	Total Debt (Qtr)
1	ABT	Abbott Laboratories	201.40 Bn	27.98	4.46	34.05 Bn
2	SYK	Stryker Corp	122.29 Bn	36.60	4.84	14.72 Bn
3	MDT	Medtronic plc	105.01 Bn	21.73	2.89	27.96 Bn
4	BSX	Boston Scientific Corp	64.81 Bn	18.16	3.14	11.03 Bn
5	EW	Edwards Lifesciences Corp	55.28 Bn	2,354.76	8.77	0.60 Bn
6	DXCM	Dexcom Inc	29.06 Bn	29.17	6.03	-
7	PHG	Koninklijke Philips Nv	29.02 Bn	22.06	1.42	9.48 Bn
8	GEHC	GE HealthCare Technologies Inc.	28.27 Bn	14.30	1.35	10.14 Bn

Research Tools

Developers

About

Investment Thesis

Peer Comparison

Research Tools

Developers

About

Investment Thesis

Peer Comparison

Create an account

Sign In

Reset Password